Dutch doctors call for EU evaluation of cost effectiveness of high cost orphan drugs.

BMJ (Clinical research ed.)

Volumn 345, Issue , 2012, Pages

  Sheldon, Tony ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

COST BENEFIT ANALYSIS; DRUG COST; DRUG MANUFACTURE; ECONOMICS; EUROPEAN UNION; HUMAN; LYSOSOME STORAGE DISEASE; NETHERLANDS; NOTE; REIMBURSEMENT;

COST-BENEFIT ANALYSIS; DRUG COSTS; EUROPEAN UNION; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; LYSOSOMAL STORAGE DISEASES, NERVOUS SYSTEM; NETHERLANDS; ORPHAN DRUG PRODUCTION;

EID: 84867391574     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e5461     Document Type: Note

References (0)